Net Deals Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Novartis to acquire cancer-focused MorphoSys for $2.9 billion

    www.aol.com/news/novartis-acquire-cancer-drug...

    (Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...

  3. Novartis raises sales growth target to 5% a year through 2027

    www.aol.com/news/novartis-lifts-sales-growth...

    The breast cancer drug was shown this year to help a wider patient group in a study, a major win for CEO Vas Narasimhan, and Novartis said it saw peak an Novartis raises sales growth target to 5% ...

  4. Novartis begins tender offer for cancer-focused MorphoSys - AOL

    www.aol.com/news/novartis-begins-tender-offer...

    BERLIN (Reuters) -Novartis said on Thursday it has launched a tender offer to acquire MorphoSys, a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion).

  5. Novartis - Wikipedia

    en.wikipedia.org/wiki/Novartis

    Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...

  6. Vasant Narasimhan - Wikipedia

    en.wikipedia.org/wiki/Vasant_Narasimhan

    Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He briefly worked at McKinsey before joining Novartis in 2005, where he has held a range of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development & Chief Medical ...

  7. Jörg Reinhardt - Wikipedia

    en.wikipedia.org/wiki/Jörg_Reinhardt

    Jörg Reinhardt. Jörg Reinhardt (born 1956, Homburg, Saarland, Germany) has been Chairman of the Board of Directors of the Swiss pharmaceutical group Novartis AG since 2013. [1] [2] Since 2017, he has also been a member of the Board of Directors of the Swiss reinsurance group Swiss Re. [3]

  8. Exclusive-Novartis in the lead to acquire cancer drug ... - AOL

    www.aol.com/news/exclusive-novartis-lead-acquire...

    (Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar ...

  9. Novartis to buy radiology drug specialist Mariana for $1 billion

    www.aol.com/news/novartis-buy-radiology-drug...

    Novartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug ...